Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for rheumatoid arthritis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Anti-interleukin-1 treatment in patients with rheumatoidarthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial The inflammatory contribution to type 2 diabetes (T2D) has suggested new therapeutic targets using biologic drugs designed for rheumatoidarthritis (RA). On this basis, we aimed at investigating whether interleukin-1 (IL-1) inhibition with anakinra, a recombinant human IL-1 receptor antagonist, could improve both glycaemic and inflammatory (...) haemoglobin (HbA1c%) (EudraCT: 2012-005370-62 ClinicalTrial.gov: NCT02236481). In total, 41 participants with RA and T2D were randomised, and 39 eligible participants were treated (age 62.72 ± 9.97 years, 74.4% female sex). The majority of participants had seropositive RA disease (rheumatoid factor and/or anticyclic citrullinated peptide antibody [ACPA] 70.2%) with active disease (Disease Activity Score-28 [DAS28]: 5.54 ± 1.03; C-reactive protein 11.84 ± 9.67 mg/L, respectively). All participants had T2D
Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoidarthritis 1 Translation of Chapters 1 to 6 of the final report A16-70 Biotechnologisch hergestellte Wirkstoffe bei rheumatoiderArthritis (Version 1.0; Status: 23 July 2019 [German original], 16 September 2019 [English translation]). Please note: This document is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. Extract IQWiG Reports – Commission No. A16-70 Biologics for rheumatoidarthritis 1 Extract of final report A16-70 Version 1.0 Biologics for rheumatoidarthritis 23 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Biologics for rheumatoidarthritis Commissioning agency: Federal Joint Committee Commission awarded on: 24 November 2016 Internal Commission No.: A16-70 Address
Rituximab as Maintenance Treatment in RheumatoidArthritis Rituximab as Maintenance Treatment in RheumatoidArthritis | CADTH.ca Find the information you need Rituximab as Maintenance Treatment in RheumatoidArthritis Rituximab as Maintenance Treatment in RheumatoidArthritis Last updated: March 29, 2019 Project Number: HO0002-000 - HE0021-000 Product Line: Technology Review Result type: Report This project reviewed the evidence on the administration of repeated courses of rituximab
Tai Chi for rheumatoidarthritis. Rheumatoidarthritis (RA) is a chronic, systemic, inflammatory, autoimmune disease that results in joint deformity and immobility of the musculoskeletal system. The major goals of treatment are to relieve pain, reduce inflammation, slow down or stop joint damage, prevent disability, and preserve or improve the person's sense of well-being and ability to function. Tai Chi, interchangeably known as Tai Chi Chuan, is an ancient Chinese health-promoting martial art (...) form that has been recognized in China as an effective arthritis therapy for centuries. This is an update of a review published in 2004.To assess the benefits and harms of Tai Chi as a treatment for people with rheumatoidarthritis (RA).We updated the search of CENTRAL, MEDLINE, Embase, and clinical trial registries from 2002 to September 2018.We selected randomized controlled trials and controlled clinical trials examining the benefits (ACR improvement criteria or pain, disease progression
Upadacitinib Versus Placebo or Adalimumab in Patients With RheumatoidArthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1-selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoidarthritis (RA) who have experienced an inadequate response to methotrexate (MTX).In total, 1,629 RA
Efficacy of Atlantoaxial Joint Glucocorticoid Injection in Patients with RheumatoidArthritis: A Randomized Trial The atlantoaxial joint (AAJ) plays a pivotal role in the cervical spine motion. Unfortunately, it is the most common cervical spine joint that is affected in patients with rheumatoidarthritis. Inflammation of the AAJ results in neck disability, nerve root compression, and finally spinal cord compression.We aim to evaluate the efficacy of intraarticular triamcinolone injection (...) of the AAJ on neck pain and disability.A prospective randomized, controlled clinical trial.An interventional pain unit in a tertiary center at a university hospital in Egypt.Sixty patients with rheumatoidarthritis complaining of AAJ arthritis were randomized into 2 groups. Group AAJI (n = 30) received AAJ injection with 1.0 mL of a mixture of 0.5 mL of bupivacaine 0.5% and 0.5 mL of 20 mg of triamcinolone, in addition to oral placebo tablets (2 tablets every 8 hours for one week). Group SS (n = 30
Rituximab (Truxima) - Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or RheumatoidArthritis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity
Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoidarthritis: 72-week data from a randomized Phase 3 trial To evaluate the efficacy and safety of CT-P10, a rituximab biosimilar after a single switch, during a multinational, randomized, double-blind Phase 3 trial involving patients with RA.Patients received 48 weeks' treatment with CT-P10 or United States- or European Union-sourced reference rituximab (US-RTX and EU-RTX, respectively). Patients entering
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe RheumatoidArthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. Patients with active rheumatoidarthritis (RA) despite treatment with biologic disease-modifying antirheumatic drug (bDMARD) therapy need treatment options.To evaluate the effects of filgotinib vs placebo on the signs and symptoms of RA in a treatment-refractory population.A 24-week
Upadacitinib as monotherapy in patients with active rheumatoidarthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Upadacitinib, an oral Janus kinase (JAK)1-selective inhibitor, showed efficacy in combination with stable background conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with rheumatoidarthritis who had an inadequate response to DMARDs. We aimed to evaluate the safety (...) and efficacy of upadacitinib monotherapy after switching from methotrexate versus continuing methotrexate in patients with inadequate response to methotrexate.SELECT-MONOTHERAPY was conducted at 138 sites in 24 countries. The study enrolled adults (≥18 years) who fulfilled the 2010 American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR) classification criteria for rheumatoidarthritis. Patients with active rheumatoidarthritis despite stable methotrexate were randomly assigned 2:2
2019LancetControlled trial quality: predicted high
How do biosimilar medications compare to their corresponding originator biologic medications in treating patients with conditions like rheumatoidarthritis or inflammatory bowel disease? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives (...) for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca May 27, 2019 It’s all in the details... or is it? Biosimilars versus biologics for inflammatory conditions. Clinical Question: How do biosimilar medications compare to their corresponding originator biologic medications in treating patients with conditions like rheumatoidarthritis or inflammatory bowel disease? Bottom Line: For patients with rheumatoidarthritis, other inflammatory
Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoidarthritis in patients with low disease activity. Anti-tumour necrosis factor (TNF) agents are effective in treating people with rheumatoidarthritis (RA), but are associated with (dose-dependent) adverse effects and high costs. To prevent overtreatment, several trials have assessed the effectiveness of down-titration compared with continuation of the standard dose. This is an update
Risk of Biologics and Glucocorticoids in Patients With RheumatoidArthritis Undergoing Arthroplasty: A Cohort Study. Patients with rheumatoidarthritis (RA) are at increased risk for infection after arthroplasty, yet risks of specific biologic medications are unknown.To compare risk for postoperative infection among biologics and to evaluate the risk associated with glucocorticoids.Retrospective cohort study.Medicare and Truven MarketScan administrative data from January 2006 through September
Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoidarthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase To evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoidarthritis (RA).This was a multi-centre, randomised
Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoidarthritis: first-year results of the randomised controlled TARA study The aim of this study is to evaluate the effectiveness of two tapering strategies after achieving controlled disease in patients with rheumatoidarthritis (RA), during 1 year of follow-up.In this multicentre single-blinded (research nurses) randomised controlled trial, patients with RA were
Adalimumab (Idacio) - Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Hidradenitis Suppurativa, Colitis, Ulcerative, Crohn Disease EMA/85985/2019 EMEA/H/C/004475 Idacio (adalimumab) An overview of Idacio and why it is authorised in the EU What is Idacio and what is it used for? Idacio is a medicine that acts on the immune system (the body’s natural defences) and is used to treat the following conditions: • plaque (...) psoriasis (a disease causing red, scaly patches on the skin); • psoriatic arthritis (a disease causing red, scaly patches on the skin with inflammation of the joints); • rheumatoidarthritis (a disease causing inflammation of the joints); • axial spondyloarthritis (inflammation of the spine causing back pain), including ankylosing spondylitis and when there are clear signs of inflammation but X-ray does not show disease; • polyarticular juvenile idiopathic arthritis and active enthesitis-related
Neuromuscular Electrical Stimulation Compared to Volitional Exercise for Improving Muscle Function in RheumatoidArthritis: A Randomized Pilot Study The aim of this study was to compare the feasibility and effectiveness of neuromuscular electrical stimulation (NMES) with that of high-intensity volitional resistance training for improving muscle structure and function and physical function in patients with rheumatoidarthritis (RA). We also compared pre-intervention and post-intervention values